ArticlePharmaceutical research2026
Continuous Electrospraying of Inhalable Biological Drug Products: Novel Formulation and Manufacturing Technology.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTraditional pharmaceutical manufacturing largely depends on batch processes that contribute to equipment downtime, higher carbon footprint, contamination risks, and elevated operational costs. Additionally, the oral delivery of biologics remains challenging due to degradation and poor gastrointestinal absorption. This study aims to develop and evaluate a continuous manufacturing platform based on electrospraying to produce a dry powder inhalation formulation of biologics.
methodA continuous electrospraying system was designed to generate core-shell structured microparticles composed of biodegradable PLGA encapsulating bovine serum albumin (BSA) and insulin. The microparticles were subsequently adhered to lactose carriers using a custom-built conveyor-belt-assisted collection setup. Particle morphology was examined via scanning electron microscopy, while protein distribution was assessed using fluorescence microscopy. Protein secondary structure and conformational stability were analyzed using FTIR and circular dichroism (CD), respectively. Encapsulation efficiency and in vitro release were quantified using UV-Vis spectroscopy.
resultsThe electrospraying process successfully produced PLGA core-shell microparticles approximately 4-20 µm in diameter, uniformly attached to lactose carrier particles. Fluorescence analysis confirmed relatively uniform protein distribution within the particles. FTIR and CD measurements indicated that the protein structure remained nearly identical to the native form, demonstrating minimal structural alteration during processing. The formulation achieved an encapsulation efficiency of 78.16%, with nearly 72% cumulative protein release within 12 h.
conclusionThe developed electrospraying-based continuous manufacturing platform demonstrates strong potential as a scalable and versatile approach for producing stable, biologic-loaded DPI formulations. Its ability to encapsulate sensitive proteins while preserving structural stability highlights its promise for future inhalable biologic delivery applications.
Indexed as
Identifiers
41807762What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.